Daytime Systolic Ambulatory Blood Pressure With a Two-Step Switch From Candesartan to Olmesartan Monotherapy and the Fixed-Dose Combination of Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL-2)

作者：Bramlage Peter^*; Zemmrich Claudia; Gansz Andrea; Sturm Claus Dieter; Fimmers Rolf; Nadal Jennifer; Schmieder Roland E; Schrader Joachim; Lueders Stephan

来源：Journal of Clinical Hypertension, 2014, 16(1): 41-46.

DOI：10.1111/jch.12227

The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10mg in patients with moderate essential hypertension not controlled on candesartan 32mg. This was a prospective, single-arm, phase IV study. The primary endpoint was the change in mean daytime systolic blood pressure (BP). A total of 77 of 89 screened patients started candesartan 32mg, 62 olmesartan 40mg, and 57 olmesartan 40mg/amlodipine 10mg. Mean daytime systolic BP was reduced by 9.8 +/- 15.2mm Hg (P<.001) vs candesartan monotherapy. Office BP reduction was 9.2 +/- 18.8/5.0 +/- 8.9mm Hg (P<0.001). Treatment goals (<140/90mm Hg for office and <135/85mm Hg for ambulatory BP) were achieved in 58.2% and 78.4% of patients, respectively. There was one drug-related adverse event (edema) and no serious adverse events. Patients of Caucasian ethnicity with moderate essential hypertension uncontrolled on candesartan experienced a further drop in BP using olmesartan and amlodipine.

• 出版日期2014-1
• 单位河北医科大学